Literature DB >> 29752301

Mitochondrial cyclophilin D regulates T cell metabolic responses and disease tolerance to tuberculosis.

Fanny Tzelepis1, Julianna Blagih2, Nargis Khan1, Joshua Gillard1, Laura Mendonca1, Dominic G Roy2, Eric H Ma2, Philippe Joubert3, Russell G Jones2, Maziar Divangahi4.   

Abstract

Mycobacterium tuberculosis (Mtb) is one of the most ancient human pathogens, yet the exact mechanism(s) of host defense against Mtb remains unclear. Although one-third of the world's population is chronically infected with Mtb, only 5 to 10% develop active disease. This indicates that, in addition to resistance mechanisms that control bacterial burden, the host has also evolved strategies to tolerate the presence of Mtb to limit disease severity. We identify mitochondrial cyclophilin D (CypD) as a critical checkpoint of T cell metabolism that controls the expansion of activated T cells. Although loss of CypD function in T cells led to enhanced Mtb antigen-specific T cell responses, this increased T cell response had no impact on bacterial burden. Rather, mice containing CypD-deficient T cells exhibited substantially compromised disease tolerance and succumbed to Mtb infection. This study establishes a mechanistic link between T cell-mediated immunity and disease tolerance during Mtb infection.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29752301     DOI: 10.1126/sciimmunol.aar4135

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  21 in total

Review 1.  Targeting innate immunity for tuberculosis vaccination.

Authors:  Shabaana A Khader; Maziar Divangahi; Willem Hanekom; Philip C Hill; Markus Maeurer; Karen W Makar; Katrin D Mayer-Barber; Musa M Mhlanga; Elisa Nemes; Larry S Schlesinger; Reinout van Crevel; Raman (Krishna) Vankayalapati; Ramnik J Xavier; Mihai G Netea
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

Review 2.  Host-directed immunotherapy of viral and bacterial infections: past, present and future.

Authors:  Robert S Wallis; Anne O'Garra; Alan Sher; Andreas Wack
Journal:  Nat Rev Immunol       Date:  2022-06-07       Impact factor: 108.555

Review 3.  Fighting Persistence: How Chronic Infections with Mycobacterium tuberculosis Evade T Cell-Mediated Clearance and New Strategies To Defeat Them.

Authors:  Laurisa Ankley; Sean Thomas; Andrew J Olive
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

4.  Live Vaccination Generates Both Disease Tolerance and Host Resistance During Chronic Pulmonary Infection With Highly Virulent Francisella tularensis SchuS4.

Authors:  Alicia M Soucy; Gregory J Hurteau; Dennis W Metzger
Journal:  J Infect Dis       Date:  2018-10-20       Impact factor: 5.226

5.  Reconsidering the Optimal Immune Response to Mycobacterium tuberculosis.

Authors:  Liku B Tezera; Salah Mansour; Paul Elkington
Journal:  Am J Respir Crit Care Med       Date:  2020-02-15       Impact factor: 21.405

Review 6.  Tuberculosis Vaccine Development: Progress in Clinical Evaluation.

Authors:  Suraj B Sable; James E Posey; Thomas J Scriba
Journal:  Clin Microbiol Rev       Date:  2019-10-30       Impact factor: 26.132

Review 7.  Host-Directed Therapy in Tuberculosis: Targeting Host Metabolism.

Authors:  Jae-Sung Kim; Ye-Ram Kim; Chul-Su Yang
Journal:  Front Immunol       Date:  2020-08-13       Impact factor: 7.561

8.  Inhibiting Histone Deacetylases in Human Macrophages Promotes Glycolysis, IL-1β, and T Helper Cell Responses to Mycobacterium tuberculosis.

Authors:  Donal J Cox; Amy M Coleman; Karl M Gogan; James J Phelan; Cilian Ó Maoldomhnaigh; Pádraic J Dunne; Sharee A Basdeo; Joseph Keane
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

Review 9.  Tolerating the Unwelcome Guest; How the Host Withstands Persistent Mycobacterium tuberculosis.

Authors:  Andrew J Olive; Christopher M Sassetti
Journal:  Front Immunol       Date:  2018-09-12       Impact factor: 7.561

Review 10.  Targeting immunometabolism in host defence against Mycobacterium tuberculosis.

Authors:  Frederick J Sheedy; Maziar Divangahi
Journal:  Immunology       Date:  2020-10-28       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.